EWA
FATE icon

Exencial Wealth Advisors’s Fate Therapeutics FATE Stock Holding History

Exencial Wealth Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,305
Closed -$252K – 465
2021
Q4 		$252K Hold
4,305
– – 0.01% 413
2021
Q3 		$255K Buy
4,305
+30
+0.7% +$2.35K 0.01% 295
2021
Q2 		$371K Sell
4,275
-175
-4% -$14.1K 0.02% 353
2021
Q1 		$367K Sell
4,450
-1,750
-28% -$168K 0.02% 322
2020
Q4 		$564K Sell
6,200
-500
-7% -$31K 0.04% 234
2020
Q3 		$268K Hold
6,700
– – 0.01% 312
2020
Q2 		$230K Buy
+6,700
New +$200K 0.02% 297

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Exencial Wealth Advisors's FATE Position: Q1 2022 in Review

Exencial Wealth Advisors sold out of Fate Therapeutics (FATE) in Q1 2022, closing a stake of 4,305 shares — an estimated $252K sold.

Exencial Wealth Advisors first reported a position in FATE in Q2 2020 and held it in 7 quarters. The position peaked at $564K in Q4 2020. 250 funds tracked by Wall St. Rank hold FATE as of Q1 2022.

  • Exencial Wealth Advisors reported no remaining Fate Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Exencial Wealth Advisors sold 4,305 Fate Therapeutics shares in Q1 2022, an estimated $252K.
  • Exencial Wealth Advisors first reported a position in Fate Therapeutics in Q2 2020 and held it in 7 quarters.
  • Exencial Wealth Advisors's Fate Therapeutics position peaked at $564K in Q4 2020.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2022.

Based on Exencial Wealth Advisors's 13F filing for Q1 2022, filed 12 May 2022.